In contrast to other gene mutations frequently found in urothelial carcinoma (UC), such as tumor protein 53 (TP53) and fibroblast growth factor receptor 3 (FGFR3), TERT promoter mutations are persistently present in both primary and recurrent tumors of most patients with NMIBC [17]. This evidence concerns the gene TERT and urothelial carcinoma.